Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis

BMC Veterinary Research

Vincenzo Miragliotta⁴  Vincenzo Di Marzo¹  Stefania Petrosino¹  Luigia Cristino¹  Maria Federica della Valle³  Francesco Albanese²  Luca Campora⁴  Francesca Abramo⁴ 

[1] Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy;Clinica Veterinaria S. Clemente, 7, Via Pietro Benvenuti, Arezzo, 52100, Italy;Science Information and Documentation Centre (CeDIS), Innovet Italia Srl, Milano, Italy;Department of Veterinary Science, University of Pisa, Viale delle Piagge 2, Pisa, 56124, Italy

关键词: Mast cells;    Palmitoylethanolamide;    Acylethanolamides;    Dog;    Atopic dermatitis;   

Others  :  1119349
DOI  :  10.1186/1746-6148-10-21

 received in 2013-10-14, accepted in 2014-01-08,  发布年份 2014

【 摘 要 】

Background

Despite the precise pathogenesis of atopic dermatitis (AD) is unknown, an immune dysregulation that causes Th2-predominant inflammation and an intrinsic defect in skin barrier function are currently the two major hypotheses, according to the so-called outside-inside-outside model. Mast cells (MCs) are involved in AD both by releasing Th2 polarizing cytokines and generating pruritus symptoms through release of histamine and tryptase. A link between MCs and skin barrier defects was recently uncovered, with histamine being found to profoundly contribute to the skin barrier defects.

Palmitoylethanolamide and related lipid mediators are endogenous bioactive compounds, considered to play a protective homeostatic role in many tissues: evidence collected so far shows that the anti-inflammatory effect of palmitoylethanolamide depends on the down-modulation of MC degranulation.

Based on this background, the purpose of the present study was twofold: (a) to determine if the endogenous levels of palmitoylethanolamide and other bioactive lipid mediators are changed in the skin of AD dogs compared to healthy animals; (b) to examine if MC number is increased in the skin of AD dogs and, if so, whether it depends on MC in-situ proliferation.

Results

The amount of lipid extract expressed as percent of biopsy tissue weight was significantly reduced in AD skin while the levels of all analyzed bioactive lipid mediators were significantly elevated, with palmitoylethanolamide showing the highest increase.

In dogs with AD, the number of MCs was significantly increased in both the subepidermal and the perifollicular compartments and their granule content was significantly decreased in the latter. Also, in situ proliferation of MCs was documented.

Conclusions

The levels of palmitoylethanolamide and other bioactive lipid mediators were shown to increase in AD skin compared to healthy samples, leading to the hypothesis that they may be part of the body’s innate mechanisms to maintain cellular homeostasis when faced with AD-related inflammation. In particular, the increase may be considered a temptative response to down-regulating the observed elevation in the number, functionality and proliferative state of MCs in the skin of AD dogs. Further studies are warranted to confirm the hypothesis.

【 授权许可】

   
2014 Abramo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y: Mast cells in atopic dermatitis. Curr Opin Immunol 2009, 21(6):666-678.
• [2]Marsella R, Samuelson D: Unravelling the skin barrier: a new paradigm for atopic dermatitis and house dust mites. Vet Dermatol 2009, 20(5–6):533-540.
• [3]Marsella R, Olivry T, Carlotti DN: Current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol 2011, 22(3):239-248.
• [4]Olivry T: Is the skin barrier abnormal in dogs with atopic dermatitis? Vet Immunol Immunopathol 2011, 144(1–2):11-16.
• [5]de Mora F, de la Fuente C, Jasmin P, Gatto H, Marco A, Ferrer L, Fondati A, Fondevila D, Torres R: Evaluation of the expression of P-selectin, ICAM-1, and TNF-alpha in bacteria-free lesional skin of atopic dogs with low-to-mild inflammation. Vet Immunol Immunopathol 2007, 115(3–4):223-229.
• [6]Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Munoz-Planillo R, Hasegawa M, Villaruz AE, Cheung GY, McGavin MJ, Travers JB, et al.: Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 2013, 503(7476):397-401.
• [7]Ando T, Matsumoto K, Namiranian S, Yamashita H, Glatthorn H, Kimura M, Dolan BR, Lee JJ, Galli SJ, Kawakami Y, et al.: Mast cells are required for full expression of allergen/SEB-Induced Skin Inflammation. J Invest Dermatol 2013, 133(12):2695-2705.
• [8]Ribatti D: Mast cells and tumours. New York: Springer; 2011.
• [9]Brown JM, Wilson TM, Metcalfe DD: The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy 2008, 38(1):4-18.
• [10]Kinet JP: The essential role of mast cells in orchestrating inflammation. Immunol Rev 2007, 217:5-7.
• [11]Nuttall T, Uri M, Halliwell R: Canine atopic dermatitis - what have we learned? Vet Rec 2013, 172(8):201-207.
• [12]Hofmann AM, Abraham SN: New roles for mast cells in modulating allergic reactions and immunity against pathogens. Curr Opin Immunol 2009, 21(6):679-686.
• [13]Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, Luger TA, Schmelz M: Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Math Neurosci 2003, 23(15):6176-6180.
• [14]Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M: Neurophysiology of pruritus: interaction of itch and pain. Arch Dermatol 2003, 139(11):1475-1478.
• [15]Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M: Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003, 139(11):1455-1458.
• [16]Metz M, Grundmann S, Stander S: Pruritus: an overview of current concepts. Vet Dermatol 2011, 22(2):121-131.
• [17]Tsujii K, Andoh T, Ui H, Lee JB, Kuraishi Y: Involvement of Tryptase and Proteinase-Activated Receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. J Pharmacol Sci 2009, 109(3):388-395.
• [18]Hammerberg B, Olivry T, Orton SM: Skin mast cell histamine release following stem cell factor and high-affinity immunoglobulin E receptor cross-linking in dogs with atopic dermatitis. Vet Dermatol 2001, 12(6):339-346.
• [19]Sugiura H, Uehara M: Mitosis of mast cells in skin lesions of atopic dermatitis. Acta Derm Venereol 1993, 73(4):296-299.
• [20]Kambe N, Kambe M, Kochan JP, Schwartz LB: Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood 2001, 97(7):2045-2052.
• [21]Scott DW: Observations on Canine atopy. J Am Anim Hosp Assoc 1981, 17(1):91-100.
• [22]Czogala JM, Marycz K, Kuryszko JJ, Zawadzki M: Cells of the skin immune system in dogs with atopy. Acta Vet Brno 2011, 80(1):11-17.
• [23]Ordeix L, Fondevila D, de Mora F, Fondati A, Ferrer L: Assessment of proliferative activity of canine dermal mast cells by bromodeoxyuridine and proliferating cell nuclear antigen labelling. Vet Dermatol 2001, 12(6):321-325.
• [24]Welle MM, Olivry T, Grimm S, Suter M: Mast cell density and subtypes in the skin of dogs with atopic dermatitis. J Comp Pathol 1999, 120(2):187-197.
• [25]Reiter LV, Torres SM, Wertz PW: Characterization and quantification of ceramides in the nonlesional skin of canine patients with atopic dermatitis compared with controls. Vet Dermatol 2009, 20(4):260-266.
• [26]Marsella R: Fixing the skin barrier: past, present and future--man and dog compared. Vet Dermatol 2013, 24(1):73-76. e17-78
• [27]Marsella R, Samuelson D, Doerr K: Transmission electron microscopy studies in an experimental model of canine atopic dermatitis. Vet Dermatol 2010, 21(1):81-88.
• [28]Baumer W, Rossbach K, Mischke R, Reines I, Langbein-Detsch I, Luth A, Kleuser B: Decreased concentration and enhanced metabolism of sphingosine-1-phosphate in lesional skin of dogs with atopic dermatitis: disturbed sphingosine-1-phosphate homeostasis in atopic dermatitis. J Invest Dermatol 2011, 131(1):266-268.
• [29]Yoon JS, Nishifuji K, Sasaki A, Ide K, Ishikawa J, Yoshihara T, Iwasaki T: Alteration of stratum corneum ceramide profiles in spontaneous canine model of atopic dermatitis. Exp Dermatol 2011, 20(9):732-736.
• [30]Gschwandtner M, Mildner M, Mlitz V, Gruber F, Eckhart L, Werfel T, Gutzmer R, Elias PM, Tschachler E: Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013, 68(1):37-47.
• [31]Salzet M, Breton C, Bisogno T, Di Marzo V: Comparative biology of the endocannabinoid system possible role in the immune response. FEBS 2000, 267(16):4917-4927.
• [32]Esposito E, Cuzzocrea S: Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev Med Chem 2013, 13(2):237-255.
• [33]Di Marzo V: PL03 Biochemistry and pharmacology of fatty acid amides – effects on inflammation, pain and pruritus and new perspectives in veterinary medicine. J Vet Pharmacol Ther 2006, 29:2-4.
• [34]Farrell EK, Merkler DJ: Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 2008, 13(13–14):558-568.
• [35]di Marzo V, Skaper SD: Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator. CNS Neurol Disord Drug Targets 2013, 12(1):4-6.
• [36]Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P: Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 2013. http://link.springer.com/article/10.1007/s10787-013-0191-7 webcite
• [37]Re G, Barbero R, Miolo A, Di Marzo V: Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007, 173(1):21-30.
• [38]Scarampella F, Abramo F, Noli C: Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol 2001, 12(1):29-39.
• [39]Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A: Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol 2010, 133(1):9-15.
• [40]De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T: Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 2011, 7:3.
• [41]Favrot C, Steffan J, Seewald W, Picco F: A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 2010, 21(1):23-31.
• [42]Shimada K, Yoon JS, Yoshihara T, Iwasaki T, Nishifuji K: Increased transepidermal water loss and decreased ceramide content in lesional and non-lesional skin of dogs with atopic dermatitis. Vet Dermatol 2009, 20(5–6):541-546.
• [43]Piekutowska A, Pin D, Reme CA, Gatto H, Haftek M: Effects of a topically applied preparation of epidermal lipids on the stratum corneum barrier of atopic dogs. J Comp Pathol 2008, 138(4):197-203.
• [44]Marsella R, Samuelson D, Doerr K, Hightower K, Harrington L: Defective barrier function in an experimental model of atopic dermatitis in high IgE producing Beagles. Dermatitis 2008, 19(4):218-238.
• [45]Inman AO, Olivry T, Dunston SM, Monteiro-Riviere NA, Gatto H: Electron microscopic observations of stratum corneum intercellular lipids in normal and atopic dogs. Vet Pathol 2001, 38(6):720-723.
• [46]Hansen HS, Moesgaard B, Hansen HH, Petersen G: N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem Phys Lipids 2000, 108(1–2):135-150.
• [47]Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S: Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008, 326(1):12-23.
• [48]Guindon J, Beaulieu P: Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 2006, 50(7):814-823.
• [49]Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, Sorrentini I, Di Marzo V: Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005, 48(8):1154-1163.
• [50]Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tuting T, Bisogno T, De Filippis D, D’Amico A, Saturnino C, et al.: Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 2010, 65(6):698-711.
• [51]De Filippis D, D’Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V, Iuvone T: Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol Res 2010, 61(4):321-328.
• [52]Berdyshev EV, Schmid PC, Dong Z, Schmid HH: Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P + cells. Biochem J 2000, 346(Pt 2):369-374.
• [53]Skaper SD, Facci L, Giusti P: Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol 2013, 48(2):340-352.
• [54]Cerrato S, Brazis P, Della Valle MF, Miolo A, Petrosino S, Di Marzo V, Puigdemont A: Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Vet J 2012, 191(3):377-382.
• [55]Campora L, Miragliotta V, Ricci E, Cristino L, Di Marzo V, Albanese F, Federica Della Valle M, Abramo F: Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. Am J Vet Res 2012, 73(7):988-995.
• [56]Sugawara K, Biro T, Tsuruta D, Toth BI, Kromminga A, Zakany N, Zimmer A, Funk W, Gibbs BF, Paus R: Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol 2012, 129(3):726-738. e728
• [57]Ambrosino P, Soldovieri MV, Russo C, Taglialatela M: Activation and desensitization of TRPV1 channels in sensory neurons by the PPARalpha agonist palmitoylethanolamide. Br J Pharmacol 2013, 168(6):1430-1444.
• [58]Benito C, Tolon RM, Castillo AI, Ruiz-Valdepenas L, Martinez-Orgado JA, Fernandez-Sanchez FJ, Vazquez C, Cravatt BF, Romero J: Beta-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-alpha, PPAR-gamma and TRPV1, but not CB(1) or CB(2) receptors. Br J Pharmacol 2012, 166(4):1474-1489.
• [59]Emerson JL, Cross RF: The distribution of mast cells in normal canine skin. Am J Vet Res 1965, 26(115):1379-1382.
• [60]Auxilia ST, Hill PB: Mast cell distribution, epidermal thickness and hair follicle density in normal canine skin: possible explanations for the predilection sites of atopic dermatitis? Vet Dermatol 2000, 11(4):247-254.
• [61]Aşti Rn KA, Kurtdede N, Ergün E, Güzel M: Mast cells in the dog skin: distribution, density, heterogeneity and influence of fixation techniques. Ankara Üniv Vet Fak Derg 2005, 52:7-12.
• [62]Wilkie JS, Yager JA, Eyre P, Parker WM: Morphometric analyses of the skin of dogs with atopic dermatitis and correlations with cutaneous and plasma histamine and total serum IgE. Vet Pathol 1990, 27(3):179-186.
• [63]Liu FT, Goodarzi H, Chen HY: IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol 2011, 41(3):298-310.
• [64]Soter NA: Morphology of atopic eczema. Allergy 1989, 44(Suppl 9):16-19.
• [65]Irani AM, Sampson HA, Schwartz LB: Mast cells in atopic dermatitis. Allergy 1989, 44(Suppl 9):31-34.
• [66]Morini M, Bettini G, Preziosi R, Mandrioli L: C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. J Histochem Cytochem 2004, 52(5):705-708.